The Associations of Insomnia Symptoms and Use of Hypnotic-Sedative Related Medications with Cardiometabolic Disease in Taiwanese Adults

• Main Authors: LIN, SHIH-CHIEH, 林士傑
• Other Authors: CHOU, YU-CHING
• Format: Others
• Language: zh-TW
• Published: 2016
• Online Access: http://ndltd.ncl.edu.tw/handle/23405418162232645671

博士 === 國防醫學院 === 生命科學研究所 === 104 === Background: Previous studies showed that both sleep duration and sleep quality (difficulty initiating or maintaining sleep, etc.) would predict the development of cardiometabolic diseases. In the clinical settings, prescription of sleep medications are classified into two major categories: Benzodiazepine (BZD) and non-BZD drugs. The primary functions of sleep medications are to induce and/or maintain sleep and to be used in the treatments of sleep disorders. Accordingly, our primary study objectives goal are to understand the relationships of cardiometabolic diseases with sleep disorders and use of common sleep medications in Taiwanese adults. Material and Methods: There are two objectives in this study. The first objective of this study was to determine the relationships of metabolic syndrome (MetS) with insomnia symptoms and sleep duration in an ethnic Chinese population. The first objective was based on participants enrolled in the Taiwanese Survey on Hypertension, Hyperglycemia and Hyperlipidemia in 2007. The second objective was to assess the relationships between the pharmacologic characteristics of sleep medications and the risk of type 2 diabetes mellitus based on the retrospective cohort analysis of the Taiwan National Health Insurance Research Database (NHIRD). Results: The results for the first study objective showed that difficulty initiating or maintaining sleep and short sleep duration were associated with the presence of MetS. In addition, findings for the second objective were demonstrated that the use of prescription of sleep medications for people with insomnia symptoms may improve the prediction of type 2 diabetes mellitus. Conclusion: Our findings suggest that insomnia symptoms and short sleep duration were associated with increased risk for cardiometabolic diseases, but the underlying mechanisms remain unclear, and further investigations are needed.